You already know from prior posts about my enthusiasm for monthly innovation tournaments, organized around enterprise-wide customer-focused themes that we hold in our offices in Alphen aan den Rijn, New York and Riverwoods, IL. Collaboration of team members across Wolters Kluwer’s tax, legal, regulatory, health, financial services, and technology shared services organizations and representing diverse skill sets (business, technology, marketing, R&D and executive management) is fruitful. Here are some emerging best practices for enterprise-wide tournaments: Read further >
In some of my previous posts I spoke about the process of continuous improvement in products to keep satisfying our customers’ needs. As information providers, we aim to offer the best products in terms of content and functionality to leverage user satisfaction. In Wolters Kluwer Italia, we just released a new BigSuite module, named InPratica, where the improvement of customer productivity is its main purpose. Read further >
Drug-drug interactions can lead to adverse drug reactions, which have high costs and may cause significant morbidity and mortality. Detecting drug-drug interactions as early as possible during a patient’s course of treatment may help to prevent some adverse drug reactions from taking place. It’s also important to be able to identify new drug-drug interactions that may result from the use of new drugs on the market. Although electronic health records (EHRs) use structured data in certain places, a large amount of the data in EHRs remains in a free text format. Read further >
Wolters Kluwer was very prominently represented at this year’s European Data Forum (EDF), the annual meeting-point for data practitioners from industry, research, the public-sector and community initiatives, where we discussed the opportunities and challenges of the emerging Data Economy in Europe.
This was my first conference, where literary all stakeholders were present – from Vice President Neelie Kroes, surrounded by police and security, who clearly stated in her welcome note the importance of the information industry for the well-being of Europe; to Greek students in T-shirt and sneakers, who were looking for information for their master’s thesis. This created an interesting atmosphere, with one key topic at the center of discussion.
The Financial Times’ Special Reports on Innovative Lawyer (global and US) reveals a lot of innovation in the legal profession. Despite a reputation for being slow to change, many law firms, corporate legal departments, law schools, and providers or legal process outsourcing are bringing comprehensive change in both the business and practice of law. Driving factors of this innovation includes several factors working together: Read further >
In previous recent posts, I described a task force I was involved in that examined why some new product development projects succeeded, while others failed. There were several common issues across the different projects we examined. In the last post, I discussed the presence and effectiveness of Project Champions. In this post, I’ll review the need to clearly define new product development projects from the start. It may be hard to believe, but some new product development projects get started before clearly defining and sharing important information with project team members, such as business and financial expectations, deadlines, scope, quality standards, purpose, target market, etc. I’m not referring here to detailed specifications and project plans (which are also essential), but rather clarifying the higher-level, end-game vision for the product. Read further >
Maybe I was wrong about wearables because I needed to go beyond my comfort zone to see what’s around the bend. I too easily settled for limits. Seymour is the project name for one of the ideas that took shape during the Innovation Tournament and while it’s a technical challenge, it may not be entirely without merit and here’s why. Read further >
In April 2011, the Food and Drug Administration (FDA) published a five-year strategic plan, entitled “Strategic Priorities 2011 – 2015.” In that plan, the FDA set forth five modernization priorities for the agency. The plan also committed to using these priorities to improve agency infrastructure, modernize the regulatory processes, strengthen its workforce, and, ultimately, do a better job promoting and protecting the health of Americans. The five modernization priorities are: Read further >
In this blog, many posts discuss how new technologies can be exploited in order to implement new systems and services to our customers. Maybe we have gone too far in looking ahead, however researchers and scholars in various fields are focusing to ensure that the human-machine interaction may take place through increasingly intelligent systems. After the Industrial one we are now in the middle of new Revolution. Read further >